Administration of EGCG after DOX treatment could enhance the expression of EGFR family ErbB2 to promote cell growth, but reduce the activity of caspase 12 and calpain 2, downregulating the expression of NF-κB p65 subunit and the downstream genes in the apoptosis pathway, during which the anticancer efficacy of DOX was increased and its IC50 on cancer cells decreased (162). Here, NFKB1 is linked to cancer.